Table 4

Correlation of anti-Hsp70 and anti-Hsp60 with symptom severities

Symptom Severity

No.

Anti-Hsp70 No. (%)

Anti-Hsp60 No. (%)

1:10

1:20

1:40

1:80

1:10

1:20

1:40

1:80


Step1: intermittent

30

2 (6.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Step2: mild persistent

36

10 (27.8)

5 (13.9)

2 (5.6)

1 (2.8)

3 (8.3)

1 (2.8)

1 (2.8)

1 (2.8)

Step3&4 moderate & severe persistent**

29

20 (69.0)

14 (48.3)

11 (37.9)

8 27.6)

14 (48.3)

5 (17.2)

4 (14.0)

4 (14.0)

R value*

0.809

0.958

0.968

0.959

0.954

0.864

0.947

0.947

P value*

0.000

0.000

0.000

0.001

0.000

0.000

0.016

0.016


* The analyses of correlation of symptom severities with different dilutions of anti-Hsp70 and anti-Hsp60

**: there are two severe persistent patients with asthma

Yang et al. Respiratory Research 2005 6:18   doi:10.1186/1465-9921-6-18

Open Data